Novo Nordisk

Wegovy’s supply + brewing competition concerns overshadow a decent Q2

04/08/22 -"In Q2, Novo continued its strong run, driven by strong growth momentum seen in both Obesity and GLP-1 Diabetes franchise. However, emerging and potential competition from Eli Lilly’s Mounjaro in ..."

PDF page sample
Pages
65
Language
English
Published on
04/08/22
Download
You may also be interested by these reports :
17/08/22
In the Q2 Lundbeck continued its solid top-line momentum, driven by strong growth seen in the main-marketed drugs. However, lower profitability due ...
17/08/22
Zantac and Biden seem to have taken the wind from even the strongest pharma groups’ sails with the sector being the worst performer last week and ...
16/08/22
To factor in the negative investor sentiment regarding the potential adverse implications of the Zantac trial in the US (expected to start by end-Aug ...
16/08/22
2Q/1H22: Strong cash position and pipeline prioritization

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO